Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13519663 | 0.89 | KCNA3 (0.43) | KCNA3ARG1ARG2GBA1 | |
| SCHEMBL8085779 | 0.89 | KCNA3 (0.43) | KCNA3ARG1ARG2GBA1 | |
| SCHEMBL18233564 | 0.89 | KCNA3 (0.43) | KCNA3ARG1ARG2GBA1 | |
| SCHEMBL11932479 | 0.88 | GBA1 (0.49) | KCNA3SPHK1GBA1OPRL1 | |
| SCHEMBL21567185 | 0.83 | KCNA3 (0.50) | KCNA3SPHK1GBA1TACR2CCR5 | |
| SCHEMBL25971506 | 0.82 | KCNA3 (0.49) | KCNA3SPHK1OPRL1 | |
| SCHEMBL9322325 | 0.81 | KCNA3 (0.41) | KCNA3ARG1ARG2SPHK1GBA1 | |
| SCHEMBL8085877 | 0.80 | CARM1 (0.52) | — | |
| SCHEMBL13519612 | 0.80 | ARG1 (0.38) | KCNA3ARG1ARG2OPRL1CCR5 | |
| SCHEMBL21025208 | 0.79 | GBA1 (0.43) | KCNA3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | LIEBER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | LIEBER INSTITUTE, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | LIEBER INSTITUTE, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-11344546-B2 | Benzamide compounds | Recurium IP Holding, LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-11318134-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090208557-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | OSCIENT PHARMACEUTICALS CORPORATION (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265092-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE | POLR2E, POLR2H, POLRMT | KCNA3 3519/4885ARG1 4730/4885ARG2 4607/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | KCNA3 1827/4885ARG1 985/4885ARG2 438/4885 |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | KCNA3 2889/4885ARG1 2302/4885ARG2 3609/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | KCNA3 3248/4885ARG1 828/4885ARG2 2078/4885 |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | REN, JAK2, ABL1 | KCNA3 2390/4885ARG1 2017/4885ARG2 1469/4885 |
| US-11318134-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | KCNA3 1827/4885ARG1 985/4885ARG2 438/4885 |
| US-20070142268-A1 | Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif | AADAC, MRPL21, HDAC6 | KCNA3 1578/4885ARG1 57/4885ARG2 67/4885 |
| US-20230257390-A1 | COMPOUNDS WHICH INHIBIT RNA POLYMERASE AND THEIR USE | POLR2E, POLR2H, POLRMT | KCNA3 3561/4885ARG1 4772/4885ARG2 4649/4885 |
| US-20090208557-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | KCNA3 3942/4885ARG1 1510/4885ARG2 2117/4885 |
| US-20080280974-A1 | Spiro compounds for treatment of inflammatory disorders | NR3C2, PTGER2, PTGER1 | KCNA3 2356/4885ARG1 993/4885ARG2 897/4885 |
| US-20230339865-A1 | QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASES | HCK, BTK, LYN | KCNA3 2930/4885ARG1 2518/4885ARG2 3183/4885 |
| US-11344546-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | KCNA3 1827/4885ARG1 985/4885ARG2 438/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | KCNA3 2254/4885ARG1 4257/4885ARG2 4681/4885 |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | KCNA3 2945/4885ARG1 2843/4885ARG2 2447/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KCNA3 3978/4885ARG1 4286/4885ARG2 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.